Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not

INTRODUCTION: Body weight can affect exposure, safety and efficacy of antibody-based therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved for wild-type RAS metastatic colorectal cancer, using a body weight–based dosing regimen. Recently, a report cited fixed-dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Michael Z, Berkhout, Marloes, Prenen, Hans, Dutta, Sandeep, Upreti, Vijay V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406372/
https://www.ncbi.nlm.nih.gov/pubmed/32801947
http://dx.doi.org/10.2147/CPAA.S262949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406372/
https://www.ncbi.nlm.nih.gov/pubmed/32801947
http://dx.doi.org/10.2147/CPAA.S262949

Ejemplares similares